A pharmaceutical formulation is provided for delivering paclitaxel in vivo comprising: paclitaxel, a water-miscible amide and a pharmaceutically-acceptable, water-miscible solubilizer selected from the group consisting of solubilizers having the general structures R.sub.1 COOR.sub.2, R.sub.1 CONR.sub.2, and R.sub.1 COR.sub.2, wherein R.sub.1 is a hydrophobic C3-C50 alkane, alkene or alkyne and R.sub.2 is a hydrophilic moiety.

Um formulation pharmaceutical é fornecido entregando o paclitaxel em compreender de vivo: o paclitaxel, um amido water-miscible e um solubilizer pharmaceutically-acceptable, water-miscible selecionados dos solubilizers consistindo do grupo que têm o general estruturam R.sub.1 COOR.sub.2, R.sub.1 CONR.sub.2, e R.sub.1 COR.sub.2, wherein R.sub.1 são um alkane C3-C50 hydrophobic, alkene ou o alkyne e R.sub.2 é um moiety hydrophilic.

 
Web www.patentalert.com

< Protein HLQDR48

< MRI system and method for producing an index indicative of alzheimer's disease

> Tissue inhibitor of metalloproteinase type three (TIMP-3) composition and methods

> Polypeptides associated with alterations in bone density

~ 00065